Evidence map›Paper›PMID 36227687›Full record

ArticleJCI insight2022

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells.

Haroon Shaikh, Joern Pezoldt, Zeinab Mokhtari, Juan Gamboa Vargas, Duc-Dung Le, Josefina Peña Mosca, Estibaliz Arellano Viera, Michael Ag Kern, Caroline Graf, Niklas Beyersdorf and 9 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Fibroblast diversity within human gut-associated lymphoid tissues.The Journal of experimental medicine · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Protective fibroblastic niches in secondary lymphoid organs.The Journal of experimental medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

Haroon ShaikhInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Joern PezoldtLaboratory of Systems Biology and Genetics, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Zeinab MokhtariInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Juan Gamboa VargasInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Duc-Dung LeInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Josefina Peña MoscaInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Estibaliz Arellano VieraInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Michael Ag KernInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Caroline GrafInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Niklas BeyersdorfGraduate School of Life Sciences, Würzburg University, Würzburg, Germany.
Manfred B LutzGraduate School of Life Sciences, Würzburg University, Würzburg, Germany.
Angela RiedelMildred Scheel Early Career Centre, University Hospital of Würzburg, Würzburg, Germany.
Maike Büttner-HeroldDepartment of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Alma ZerneckeInstitute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
Hermann EinseleDepartment of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Antoine-Emmanuel SalibaHelmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection (HZI), Würzburg, Germany.
Burkhard LudewigInstitute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Jochen HuehnDepartment of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Andreas BeilhackInterdisciplinary Center for Clinical Research (IZKF), Experimental Stem Cell Transplantation Laboratory, and.
Universitätsklinikum Würzburg · DEUniversity of Würzburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHelmholtz Centre for Infection Research · DEHelmholtz Institute for RNA-based Infection Research · DEMedizinische Hochschule Hannover · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute graft versus host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT) inflicted by alloreactive T cells primed in secondary lymphoid organs (SLOs) and subsequent damage to aGvHD target tissues. In recent years, Treg transfer and/or expansion has emerged as a promising therapy to modulate aGvHD. However, cellular niches essential for fostering Tregs to prevent aGvHD have not been explored. Here, we tested whether and to what extent MHC class II (MHCII) expressed on Ccl19+ fibroblastic reticular cells (FRCs) shape the donor CD4+ T cell response during aGvHD. Animals lacking MHCII expression on Ccl19-Cre-expressing FRCs (MHCIIΔCcl19) showed aberrant CD4+ T cell activation in the effector phase, resulting in exacerbated aGvHD that was associated with significantly reduced expansion of Foxp3+ Tregs and invariant NK T (iNKT) cells. Skewed Treg maintenance in MHCIIΔCcl19 mice resulted in loss of protection from aGvHD provided by adoptively transferred donor Tregs. In contrast, although FRCs upregulated costimulatory surface receptors, and although they degraded and processed exogenous antigens after myeloablative irradiation, FRCs were dispensable to activate alloreactive CD4+ T cells in 2 mouse models of aGvHD. In summary, these data reveal an immunoprotective, MHCII-mediated function of FRC niches in secondary lymphoid organs (SLOs) after allo-HCT and highlight a framework of cellular and molecular interactions that regulate CD4+ T cell alloimmunity.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsMiceMice, Inbred BALB CMice, Inbred C57BLT-Lymphocytes, RegulatoryAntigen-presenting cellsHematologyMHC class 2Stem cell transplantationTransplantation

Identifiers

PMID36227687
PMCPMC9746820
OpenAlexW4305013930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.